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Genome-wide association studies have linked common vari-
ation in ZNF804A with an increased risk of schizophrenia. 
However, little is known about the biology of ZNF804A and 
its role in schizophrenia. Here, we investigate the function 
of ZNF804A using a variety of complementary molecu-
lar techniques. We show that ZNF804A is a nuclear pro-
tein that interacts with neuronal RNA splicing factors and 
RNA-binding proteins including RBFOX1, which is also 
associated with schizophrenia, CELF3/4, components of 
the ubiquitin-proteasome system and the ZNF804A para-
log, GPATCH8. GPATCH8 also interacts with splicing 
factors and is localized to nuclear speckles indicative of a 
role in pre-messenger RNA (mRNA) processing. Sequence 
analysis showed that GPATCH8 contains ultraconserved, 
alternatively spliced poison exons that are also regulated 
by RBFOX proteins. ZNF804A knockdown in SH-SY5Y 
cells resulted in robust changes in gene expression and pre-
mRNA splicing converging on pathways associated with 
nervous system development, synaptic contact, and cell 
adhesion. We observed enrichment (P  =  1.66  ×  10–9) for 
differentially spliced genes in ZNF804A-depleted cells 
among genes that contain RBFOX-dependent alternatively 
spliced exons. Differentially spliced genes in ZNF804A-
depleted cells were also enriched for genes harboring de 
novo loss of function mutations in autism spectrum disor-
der (P = 6.25 × 10–7, enrichment 2.16) and common variant 
alleles associated with schizophrenia (P  =  .014), bipolar 
disorder and schizophrenia (P = .003), and autism spectrum 
disorder (P = .005). These data suggest that ZNF804A and 
its paralogs may interact with neuronal-splicing factors 
and RNA-binding proteins to regulate the expression of a 
subset of synaptic and neurodevelopmental genes.
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Introduction
Schizophrenia is a highly heritable neuropsychiatric dis-
order that is often associated with poor quality of life 
and premature mortality.1–3 Risk is conferred by many 
common alleles of individually weak effect (collectively 
accounting for up to 40% of disease liability4), as well as 
rare alleles, some of stronger effect. Genome-wide asso-
ciation studies (GWAS) have identified large numbers of 
common genetic variants associated with an increased 
risk in schizophrenia,5–8 with the most recent study 
reporting 179 independent associations mapping to 145 
independent loci.7 One of the first variants implicated 
in schizophrenia through GWAS was rs1344706, within 
intron 2 of ZNF804A. Following the original GWAS, 
the association between rs1344706 and schizophrenia 
has been independently replicated in large meta-analyses 
of schizophrenia and in a combined analysis of schizo-
phrenia and bipolar disorder.7–11 Although GWAS alone 
do not definitively identify causal variants, rs1344706 is 
one of only 5 single-nucleotide polymorphisms (SNPs), 
all intronic, that collectively have a 95% posterior prob-
ability of including the causal SNP at this locus.7 The risk 
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allele of rs1344706 is associated with decreased messenger 
RNA (mRNA) levels during the second trimester of fetal 
brain development.12 Allelic variants at rs1344706 have 
been shown to differentially bind to an unidentified pro-
tein in nuclear extracts prepared from SH-SY5Y cells and 
neural progenitors cells (NPCs)13 and are associated with 
expression of an alternatively spliced ZNF804A tran-
script, lacking the region encoding the zinc finger domain, 
in fetal brain.14 ZNF804A variants have also been shown 
to be associated with aspects of working memory per-
formance, cognition, and a range of neuropsychological 
traits.15,16 Furthermore, neuroimaging studies have found 
that rs1344706 is associated with functional connectivity 
in healthy individuals and patients with schizophrenia 17,18 
and neural activity in healthy controls.19
At the time of its initial discovery as being associ-
ated with schizophrenia, the function of ZNF804A was 
unknown.20 Sequence analysis showed that ZNF804A 
and its 2 paralogs in the human genome, ZNF804B and 
GPATCH8 (see later), contain a single C2H2-type zinc fin-
ger domain that in other proteins has been shown to bind 
directly to DNA, RNA, protein, and lipids.21,22 Several 
studies have addressed the biological role of ZNF804A. 
These have implicated ZNF804A in a number of cellu-
lar processes including regulation of gene expression, 
protein translation, neuronal migration, and dendritic 
spine structure.23–25 Transient knockdown of ZNF804A 
in human NPCs was found to result in the differential 
expression of genes enriched for the Gene Ontology 
(GO) process cell adhesion26 whereas stable knockdown 
of ZNF804A in human induced pluripotent stem cells-
derived NPCs resulted in the differential expression of 
genes in the interferon signaling pathway.27
Although these studies suggest that ZNF804A may 
have regulatory activity at the transcriptional or transla-
tional level, its precise molecular function is still unknown. 
Here, we provide the first evidence that ZNF804A inter-
acts with proteins that have defined roles in pre-mRNA 
processing and alternative splicing, including RBFOX1 
that is also associated with schizophrenia.7 These data 
are further corroborated by knockdown of ZNF804A in 
SH-SY5Y cells, which results in robust changes in gene 
expression and alternative splicing particularly in syn-
aptic and neurodevelopmental genes, many of which are 
RBFOX targets. These data suggest that ZNF804A may 
regulate the expression and splicing of neurodevelop-
mental genes, some of which have been implicated in the 
genetic etiology of autism spectrum disorder (ASD) and 
schizophrenia.
Materials and Methods
Yeast 2-Hybrid Screens
Yeast 2-hybrid (Y2H) screens were performed using 
baits encompassing amino acids 1–620 and 621–1209 
of human ZNF804A (NCBI RefSeq NM_194250.1) 
and amino acids 1–242 and 88–1505 of mouse Gpatch8 
(NCBI RefSeq NM_001159492.1) as described previ-
ously.28 Each bait was screened against an adult mouse 
brain complementary DNA (cDNA) library (Invitrogen). 
In addition, the ZNF804A baits were used to screen a 
human fetal brain (Invitrogen). Gene set enrichment 
analysis on the list of ZNF804A interactome was per-
formed using the ToppGene suite.29 Detailed molecular 
biology methods can be found in the accompanying sup-
plementary material.
Cell Culture, RNA Interference, and Microarrays
SH-SY5Y cells were transfected with small interfering RNA 
(siRNA) duplexes using Lipofectamine RNAi MAX (Life 
Technologies) according to manufacturer’s instructions. 
Briefly, SH-SY5Y cells were seeded in 12-well plates (5 × 104 
cells per well) in Dulbecco’s modified Eagle’s Medium sup-
plemented with 5% (v/v) fetal calf serum. Adherent cells 
were transfected with ZNF804A-specific siRNA (siZNFA 
[exon 2], 5ʹ-GGAAAAUACCAUAGCAAAAUU; siZNFB 
[exon  3], 5ʹ-CCAGGAAAGAUGAAAGAAAUU 
[Dharmacon]) or glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH)-specific siRNA (siGAP, 
5ʹ-GUCAACGGAUUUGGUGUAUU) at a final con-
centration of 50 nM (3 wells per condition). The growth 
media was changed 24 hours post-transfection and the fol-
lowing day the transfection protocol was repeated. After 
a further 48 hours, cells from the 3 wells were pooled and 
RNA extracted.
Affymetrix GeneChip Human 1.0 ST microarrays were 
processed and analyzed at the Central Biotechnology 
Services facility at Cardiff  University. Briefly, total RNA 
from SH-SY5Y cells was extracted using and labeled with 
the GeneChip WT Terminal Labeling Kit (Affymetrix) 
according to the manufacturer’s instructions. Two siR-
NAs targeting different exons of ZNF804A were analyzed 
alongside 2 negative controls; siGAP- and mock-treated 
cells (n  =  4 per condition). Exon array data were ana-
lyzed using tools in Partek Genomic Suite 6.4 software 
(Partek Inc.). Analysis was restricted to the core Meta-
probe set that represents 17 881 RefSeq genes and full-
length GenBank mRNAs. Probe intensities were quantile 
normalized and a pre-background adjustment performed 
based on the guanine-cytosine (GC) content of the probe 
sequence. Background correction was performed using 
the robust multiarray analysis algorithm.30 To detect any 
outlier samples, overall gene expression was analyzed by 
means of a principle component analysis and clustering 
analysis. All arrays met the quality parameters established 
by Affymetrix and no outliers were detected. The probe 
set expression values were summarized to gene-level 
expression values using the probe set mean. Gene expres-
sion changes were identified using a 1-way ANOVA on 
gene-summarized probe set intensities after multiple test 
correction using a false discovery rate (FDR) of 0.01.
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Exon Array Identification of Alternative 
Splicing Events
Alternative splicing events were identified using both probe-
level and exon-level intensities. Briefly, pre-analysis filtra-
tion a cutoff of log2 signal intensity more than 3 was used 
to remove probe sets not expressed in at least one group.31 
Alternative splicing events were identified using an alterna-
tive splicing 1-way ANOVA on gene-summarized probe 
set logarithmic intensities. Knockdown type (ZNF804A 
knockdown vs GAPDH knockdown or mock transfec-
tion) was chosen as the candidate variable in the ANOVA 
model to obtain ZNF804A-associated splicing events. 
Alternatively spliced genes (P < 1 × 10–6, Bonferroni cor-
rected) were selected for downstream analysis.31,32 This list 
was also filtered to exclude genes without Human Genome 
Organisation (HUGO) symbols and transcript clusters 
with less than 5 probe sets. We also used probe-level expres-
sion changes to discover additional alternatively spliced 
exons.33 Accordingly, we determined further putative alter-
native splicing events based on the criteria of significantly 
differentially expressed probe sets (FDR 0.05) in genes that 
were not differentially expressed (Pdifferential expression > .05).
Gene Set Enrichment Analysis
For GO enrichment analysis, lists of differentially 
expressed (DEX) or differentially spliced genes were 
entered into the commercial GeneGo MetaCore path-
way analysis software (Thomson Reuters) and tested 
for enrichment in Maps, Diseases, GeneGO process net-
works, and GO processes using a hypergeometric model. 
In addition, we also used the publicly available Database 
for Annotation, Visualization and Integrated Discovery 
(DAVID) Bioinformatic Resource 6.8 for further pathway 
analysis.34 Enrichment analysis using functional genes 
sets (RBFOX and CELF4) was performed using Fisher’s 
exact test implemented in STATA 12.0 or R as described 
previously.35 For all tests, we considered the list of DEX 
genes (n = 546) and differentially spliced genes (n = 972) 
in ZNF804A-depleted cells (extended data set 1). Gene 
sets comprising RBFOX splicing targets, CELF4 and 
TCF4 and bound genes and transcripts were obtained 
from Weyn-Vanhentenryck et  al and Wagnon et  al.36,37 
Enrichment of DEX and differentially spliced genes at 
GWAS risk loci was determined using the multi-marker 
analysis of genomic annotation (MAGMA) package 
using a window of 35 kb upstream and 10 kb downstream 
with the whole genome as background.38,39 Summary sta-
tistics were obtained from the clozapine UK (CLOZUK) 
and Psychiatric Genomics Consortium’s (PGC) schizo-
phrenia study (CLOZUK + PGC2), the PGC’s bipo-
lar disorder and schizophrenia working group study 
and the Lundbeck Foundation Initiative for Integrative 
Psychiatric Research (iPSYCH) common risk variants in 
ASD study.7,40,41 SNPs with information (INFO) scores 
more than 0.6 were retained as described previously.7 
Variants within the major histocompatibility complex 
(MHC) region were removed as in previous studies of 
enrichment given it is not possible to adequately control 
for the complex patterns of long range linkage disequi-
librium (LD) in this region.7 Lists of genes containing de 
novo variants (loss of function [LoF], missense, and syn-
onymous) identified in patients (schizophrenia, ASD, and 
intellectual disability [ID]) and controls were obtained 
from Genovese et al.42 Genes that were DEX or differen-
tially spliced in ZNF804A-depleted cells were tested for 
enrichment for de novo variants in schizophrenia, ASD, 
and ID controls using denovolyzeR.43
Results
The ZNF804A Interactome
To gain insights into the function of ZNF804A, we used 
the Y2H system to find ZNF804A-interacting proteins. 
Two baits spanning the entire coding sequence of human 
ZNF804A were used to screen human embryonic brain 
and adult mouse brain cDNA libraries (figure 1A). These 
screens identified multiple interacting clones from each 
library (figure 1B), including several proteins with nucleic 
acid-binding domains (splicing and transcription factors) 
and components of the ubiquitin-proteome system (UPS). 
The splicing factors RNPS1 and RBFOX2 and a subunit of 
the proteasome (PSMA3) were identified in both the human 
and mouse libraries. In addition to RNPS1 and RBFOX2, 
the splicing factors, RBFOX1 and NOVA2, and the 
RNA-binding proteins CELF3 (BRUNOL1) and CELF4 
(BRUNOL4) were found to interact with ZNF804A in 
yeast. Interestingly, the ZNF804A paralog GPATCH8 was 
found in the ZNF804A interactome, suggesting a physical 
interaction between these proteins (figure 1B).
GPATCH8 contains an N-terminal G-patch domain and 
coiled coil regions flanking the C2H2 zinc finger domain. 
G-patch domains are found in some RNA-binding proteins 
including components of the spliceosomal complex.44 Having 
found evidence for a physical interaction between GPATCH8 
and ZNF804A, we re-screened the adult mouse brain cDNA 
library to find additional GPATCH8-interacting proteins. 
These experiments showed that GPATCH8 interacts with 
UPS components (PSMA3 and UBE2I) and the splic-
ing factors RNPS1 and SRSF11. The interaction between 
GPATCH8 (KIAA0553), RNPS1, and SRSF11 (p54) has 
been reported previously in HeLa cells demonstrating the 
efficacy and reproducibility of the Y2H system in iden-
tifying robust protein-protein interactions.45 The entire 
ZNF804A interactome was used for pathway analysis using 
the ToppGene software suite (figure  1C).29 This analysis 
showed that the ZNF804A network was enriched for several 
GO processes including regulation of alternative mRNA 
splicing, via spliceosome (GO:0000381, P = 8.78 × 10–6) and 
RNA binding (GO:0003723, P = 8.47 × 10–6).
To further examine the molecular function of 
ZNF804A and its paralog GPATCH8, we expressed 
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constructs encoding each protein in heterologous cells. 
We were unable to detect the endogenous ZNF804A 
protein in brain (wild-type and Zfp804a mutant mice) 
or SH-SY5Y neuroblastoma cells (see later) using either 
commercially available antibodies or antisera devel-
oped “in-house.” However, ZNF804A was detected in 
transfected cells following proteasome inhibition with 
lactacystin (supplementary figure  S1A). These data are 
consistent with the multiple interactions of ZNF804A 
and GPATCH8 with UPS components and also suggest 
that ZNF804A levels may be tightly regulated. Confocal 
microscopy revealed that ZNF804A was predominantly 
localized to the nucleus of transfected cells (supplemen-
tary figure  S1B). For comparative purposes, we also 
Fig. 1. The ZNF804A interactome. Schematic depicting the domain architecture of ZNF804A and its paralog GPATCH8 (A). 
Images were produced using SMART and are annotated to show protein domains and motifs. GPATCH8 differs from ZNF804A at its 
N-terminus where the larger protein contains a G-patch domain and an extensive coiled-coil region (green). GPATCH8 also contains 
a higher proportion of low complexity protein sequence (pink) than its paralog. The bisecting lines show the location of the coding 
exon boundaries in the 2 proteins. The position of the Y2H baits (a-d) is shown below each protein. Protein-protein interaction (PPI) 
network for ZNF804A and GPATCH8 (B). PPI was produced in CYTOSCAPE and shows combined Y2H data from the four baits 
depicted in panel A. Interacting genes are color-coded according to molecular function; baits, yellow; messenger RNA processing and 
binding, orange; RNA-associated, purple; transcription, red; ubiquitin-proteasome, green; unspecified, light blue. Gene Ontology (GO) 
enrichment for the entire ZNF804A interactome (C). Enrichment analysis was performed on the list of interactors using ToppGene. The 
top 3 statistically significant GO molecular function (red) and GO biological processes (green) are shown after Bonferroni correction.
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cloned the murine ortholog of GPATCH8 (Gpatch8) 
from brain. Sequence analysis revealed that Gpatch8 con-
tained 2 poison cassette exons flanking exon 4 (encod-
ing the G_patch domain), whose inclusion would result 
in premature translational termination (supplementary 
figure S1C). Poison exons are ultraconserved sequences 
containing in-frame stop codons that prematurely ter-
minate translation.46 All members of the serine/arginine-
rich family of splicing factors such as SRSF11 (figure 1B) 
and SRSF2 (SC35; supplementary figure  S1E) contain 
poison exons that are thought to autoregulate protein 
levels by self-splicing, coupling alternative splicing to 
nonsense-mediated decay of the unspliced transcript.46 
G_patch domain-containing proteins are enriched 
for GO processes including nucleic acid binding and 
mRNA processing (supplementary figure S1D). Finally, 
Gpatch8 was only detected in the nucleus of transfected 
cells where it appeared to be localized to nuclear speck-
les, subnuclear structures (labeled with SC35) that are 
enriched in pre-mRNA splicing factors (supplementary 
figure S1E).47 Together, our data suggest that ZNF804A 
and GPATCH8 are involved in pre-mRNA processing 
and alternative splicing.
ZNF804A Knockdown in SH-SY5Y Cells
To test the hypothesis that ZNF804A may be involved the 
regulation of gene expression and pre-mRNA processing, 
we used siRNAs to knockdown endogenous ZNF804A 
in the SH-SY5Y neuroblastoma cell line. SH-SY5Y cells 
express similar levels of ZNF804A to those found in 
the brain and have been used for functional analysis of 
many neuropsychiatric risk genes including ZNF804A 
itself.24,35,48 Two siRNA duplexes, siZNFA (exon 2)  and 
siZNFB (exon 3), were designed to knockdown ZNF804A. 
In addition to the siRNAs targeting ZNF804A, we used a 
duplex targeting GAPDH (siGAP) and mock-transfected 
cells as controls. The siGAP duplex was chosen because it 
has minimal off-target effects while activating the RNA-
induced silencing complex pathway in transfected cells. 
RNAi-mediated knockdown of each gene was deter-
mined by quantitative polymerase chain reaction (qPCR) 
on first strand cDNA prepared from each experimental 
condition. We observed an average 81% (SD, 8.4) and 
77% (SD, 8.8) reduction in ZNF804A mRNA using 
siZNFA and siZNFB, respectively when compared with 
mock-treated and siGAP-treated cells (supplementary fig-
ure S2A). Similarly, we observed an 86% (SD, 3.2) reduc-
tion in GAPDH mRNA using siGAP (supplementary 
figure S2B). Thus, transfection of each duplex resulted in 
robust knockdown of its target.
RNA samples from siRNA-treated cells and controls 
(siZNFA, siZNFB, siGAP, and mock-transfected; n = 4) 
were converted to cDNA and hybridized to the exon array. 
Data quality assessment identified no outlier arrays using 
Expression Console Software, thus data from all arrays 
were included in the subsequent analyses. Signal intensity 
data from knockdown of ZNF804A using siZNFA and 
siZNFB were grouped before analysis to give the siZNF-
Pooled dataset. This ensures that any changes seen were a 
result of ZNF804A knockdown and not due to off-target 
effects of the individual siRNAs. Analyzing the 17 881 
genes represented in the core probe set list we identified 
a total of 579 genes (FDR 0.01) that showed differential 
expression between siZNFPooled and siGAP (extended 
data set 1). By contrast, only 47 genes were DEX follow-
ing GAPDH knockdown. qPCR was used to validate the 
gene expression changes in ZNF804A-depleted cells that 
were identified using the exon array. Eight DEX genes 
(SPARC, FSTL4, NPY, PDK1, EGR1, TMEFF2, CCL2, 
and EFNB2) that had a single isoform were selected for 
independent validation by qPCR. In each case, qPCR lev-
els were in close agreement with the fold change detected 
on the microarray thereby confirming the utility of the 
exon array to detect robust gene expression changes in 
ZNF804A-depleted cells (supplementary table S2).
Having shown that ZNF804A interacts with proteins 
involved in pre-mRNA processing (figure 1), we used the 
microarray data to search for alternatively spliced exons 
that were differentially expressed in ZNF804A-depleted 
cells. We investigated the exon-level changes following 
ZNF804A knockdown using 2 methods. First, we applied 
an alternative splicing ANOVA to gene-summarized 
probe set intensities along with several filtration criteria. 
We identified candidate alternative splicing events in 448 
genes (extended data set 1). Second, we selected individual 
probe sets with differential expression in genes that were 
not DEX.33,49 This analysis identified 566 differentially 
expressed individual probe sets after ZNF804A knockdown 
(extended data set 1). In control experiments, we compared 
differential splicing in the GAPDH-knockdown cells with 
mock-transfected cells using gene-summarized probe set 
intensities as described previously. Consistent with the 
rationale that GAPDH encodes a metabolic enzyme that is 
not known to have a role in alternative splicing, we identi-
fied only 13 differentially spliced genes in siGAP-treated 
cells compared with the mock-transfected controls using 
the same statistical parameters (data not shown).
qPCR and reverse transcription PCR (RT-PCR) were 
used to validate differential alternative splicing events 
identified using both of the methods described earlier. 
We focused on genes that contained previously annotated 
splicing events by comparing the Partek geneview for 
each gene with their the University of California, Santa 
Cruz (UCSC) entry. For example, the geneview of ENAH 
(enabled homologue—actin regulator) showed increased 
exclusion of exon 11a (chr1:225692693-225692755) 
following ZNF804A knockdown (P  =  8.2  ×  10–4; fold 
change  =  –2.69; 1-way ANOVA) and that the ENAH 
transcript was not differentially expressed (figure  2A). 
This alternative splicing event was also annotated in the 
UCSC RefSeq database indicating that it corresponds 
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Fig. 2. Alternative splicing events in ZNF804A-depleted cells. Geneview for ENAH after ZNF804A knockdown (A). Following 
ZNF804A knockdown there was increased exclusion of the exon 11a (highlighted with an oval). Screenshot showing the genomic region 
containing ENAH exon 11a and flanking exons displayed using the UCSC Genome Browser (B). Reverse transcription polymerase chain 
reaction (RT-PCR) using primers complementary to the constitutive exons flanking ENAH exon 11a (C). Quantitative PCR (qPCR) 
using primers complementary to exon 11a and a control pair complementary to another region on the transcript (D). The expression 
of exon 11a was compared between samples using the ∆∆Ct method with the control primer set as the endogenous normalizer. The 
bar graph shows the percentage abundance of exon 11a relative to the glyceraldehyde-3-phosphate dehydrogenase-specific siRNA 
(siGAP)-treated sample. The error bars represent the standard deviation of the raw Ct values. The significance was assessed using a 
1-way ANOVA and Tukey’s post-hoc test. ** P < .05. PTPRR isoform switch in ZNF804A-depleted cells (D). PTPRR geneview showed 
a switch in transcript variant use in ZNF804A-depleted cells. qPCR using the primers complementary to each transcript of PTPRR 
(E). The expression of each PTPRR transcript was compared between samples using the ∆∆Ct method with beta actin (ACTB) set as 
the endogenous normalizer. The bar graph shows the relative abundance of each PTPRR transcript relative to the abundance of the 
canonical transcript (NM_130846.2) in the siGAP-treated sample. NM_002849 (canonical membrane bound).
D
ow
nloaded from
 https://academ
ic.oup.com
/schizophreniabulletin/advance-article-abstract/doi/10.1093/schbul/sby183/5266796 by C
ardiff U
niversity user on 02 January 2019
Page 7 of 12
ZNF804A Is a Regulator of Pre-mRNA Processing and Gene Expression
to a sequence-validated event in a proportion of ENAH 
transcripts (figure 2B) and is known to be regulated by 
RBFOX splicing factors.50,51 The results of RT-PCR were 
consistent with those from the microarray analysis, with a 
reduction in the longer, exon 11a containing ENAH tran-
script in ZNF804A-depleted cells (figure 2C). These data 
were further confirmed by qPCR, which showed approxi-
mately 50% reduction in ENAH exon 11a inclusion after 
ZNF804A knockdown relative to both controls (P < .01; 
figure 3D). Together, these data validate the exon array, 
showing that exon 11a of ENAH is differentially spliced 
(excluded) in ZNF804A-depleted cells.
In addition to changes in cassette exon splicing, the 
alternative splicing ANOVA identified changes in alter-
native transcript usage after ZNF804A knockdown. 
The geneview of PTPRR (encoding protein tyrosine 
phosphatase receptor type R) showed differential 5ʹ-end 
usage, indicative of a switch in transcript usage between 
transcripts encoding the soluble and membrane bound 
isoforms of the receptor in ZNF804A-depleted cells (fig-
ure  2E).52 This switch in transcript variant usage was 
confirmed by qPCR and showed that the membrane 
bound and soluble isoforms of PTPRR arise from the 
differential use of alternative transcriptional start sites 
as described previously (figure 2F).53 We also confirmed 
several other differential alternative splicing events in 
ZNF804A-depleted cells (supplementary table S3).
Pathway and Gene Set Analysis for 
DEX and Differentially Spliced Genes in 
ZNF804A-Depleted Cells
We used the GeneGo MetaCore bioinformatics pack-
age and the DAVID bioinformatics resource to search 
for pathways and networks enriched for genes with 
altered expression or splicing in ZNF804A-depleted 
cells. MetaCore was chosen because the analysis soft-
ware utilizes both GO processes and GeneGo’s manu-
ally curated processes and pathways. Of the 579 DEX 
genes, 547 had known HUGO IDs and were used for 
enrichment and pathway analysis. MetaCore enrichment 
analysis of the DEX genes showed that the most sig-
nificant GO biological processes were neuron projection 
development (P  =  3.35  ×  10–15), cell projection organi-
zation (P  =  1.96  ×  10–14), and nervous system develop-
ment (P = 2.66 × 10–14) (figure 3A). Enrichment analysis 
using GeneGo networks highlighted synaptic contact as 
an element of cell adhesion (P = 8.39 × 10–6) and axonal 
guidance as an element of neurogenesis and development 
(P = 4.5 × 10–4) (figure 3B). Similarly, we used MetaCore 
to search for GO processes associated with differen-
tially spliced genes in ZNF804A-depleted cells. For these 
analyses, we used both sets of alternatively spliced genes 
identified using the gene-level and exon-level ANOVAs. 
This analysis identified GO processes relating to neuro-
nal and cell projection organization and morphogenesis 
as enriched for differential splicing events in ZNF804A-
depleted cells (figure 3C). Similar results were obtained 
using DAVID (extended data set 1).
Having found that RBFOX1/2 and CELF4 directly 
interact with ZNF804A, we determined whether DEX 
and differentially spliced genes in ZNF804A-depleted 
cells were enriched for RBFOX and CELF4 targets. 
We found that genes that were differentially spliced 
in ZNF804A-depleted cells were highly enriched for 
RBFOX targets (P = 3.31 × 10–9, OR 2.32) whereas no 
enrichment was found among the DEX genes (table 1). 
By contrast, no enrichment was observed for DEX or dif-
ferentially spliced genes in ZNF804A-depleted cells and 
transcripts bound by CELF4 (table 1).
Given the extensive evidence for pleiotropy across neu-
ropsychiatric disorders,2 we examined the enrichment of 
DEX and differentially spliced genes for common vari-
ants associated with schizophrenia, schizophrenia and 
bipolar disorder, and ASD. MAGMA was used to test for 
common variant association based on data from the most 
recent GWAS7,40,41 correcting for gene length and LD.38 
We found enrichment of differentially spliced genes (in 
ZNF804A-depleted cells) among common variant alleles 
associated with schizophrenia (P = .014), bipolar disor-
der and schizophrenia (P = .003), and ASD (P = .005). 
By contrast, no enrichment was found between DEX 
genes among common variant alleles in the three GWAS 
described previously. Finally, we used denovolyzeR43 to 
test for enrichment of DEX and differentially spliced 
genes among de novo mutations in schizophrenia, ASD, 
and ID.42,54 Differentially spliced genes were enriched for 
all classes of nonsynonymous mutation in ASD, includ-
ing the most damaging, LoF mutations (P = 6.25 × 10–7, 
enrichment 2.16) (table  2). There was also enrichment 
(P = 1.92 × 10–3, enrichment 2.31) for genes harboring 
LoF mutations in ASD and DEX genes in ZNF804A-
depleted cells (supplementary table  S4). No enrich-
ment was observed between any class of schizophrenia, 
ID-associated and control/sibling de novo mutations and 
differentially spliced or DEX genes in ZNF804A-depleted 
cells (table 2; supplementary table S4).
Discussion
Despite strong support for the candidacy of ZNF804A 
as a schizophrenia susceptibility gene, very little is known 
about the function of the protein and how alteration in its 
function or expression might contribute to the molecular 
pathology of the disorder.55 To address this, we examined 
the function of ZNF804A at the molecular level, using 
a combination of techniques to identify ZNF804A-
interacting proteins and ZNF804A-regulated genes in a 
cellular model. We show that ZNF804A and its paralog 
GPATCH8 interact with a number of RNA-binding pro-
teins and pre-mRNA splicing factors, including members 
of the RBFOX family that regulate alternative mRNA 
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Fig. 3. Enrichment analysis of differentially expressed (DEX) and differentially spliced genes in ZNF804A-depleted cells. The lists of 
DEX and differentially spliced genes between ZNF804A-specific siRNA-treated and glyceraldehyde-3-phosphate dehydrogenase-specific 
siRNA-treated samples (FDR 0.01) were imported into GeneGo Metacore. The bar charts show the top ranked Gene Ontology (GO) 
Processes (A, DEX) and (C, alternative splicing) and GeneGo Process Networks (B, DEX) identified by the enrichment analysis after 
multiple test correction (FDR 0.05). In all cases, only ontologies that pass multiple test correction are shown.
D
ow
nloaded from
 https://academ
ic.oup.com
/schizophreniabulletin/advance-article-abstract/doi/10.1093/schbul/sby183/5266796 by C
ardiff U
niversity user on 02 January 2019
Page 9 of 12
ZNF804A Is a Regulator of Pre-mRNA Processing and Gene Expression
splicing in neurons.56 Knockdown of ZNF804A resulted 
in differential expression of genes involved in nervous 
system development and synaptic contact and was associ-
ated with changes in alternative splicing of genes that are 
also RBFOX targets. Collectively, these data suggest that 
ZNF804A associates with a range of RNA-binding pro-
teins to regulate pre-mRNA processing in neuronal cells.
In this study, we show for the first time that ZNF804A 
interacts with proteins involved in pre-mRNA process-
ing, transcriptional regulators, and UPS components 
(figure 1B). Notably, ZNF804A was found to interact with 
splicing factors including RBFOX1/2 and mRNA-bind-
ing proteins such as CELF3/4.56 RBFOX1 has recently 
been implicated in schizophrenia in the largest published 
GWAS of the disorder7 and moreover, the targets of both 
RBFOX proteins and CELF4 are enriched for rare dis-
ruptive exonic mutations in people with schizophrenia.42 
Given the number of RNA-binding proteins that interact 
with ZNF804A, we propose that ZNF804A is involved 
mRNA metabolism and alternative splicing. The inter-
action between ZNF804A and its paralog GPATCH8 
lends further support to this hypothesis as follows. The 
G_patch is an RNA-binding domain that is required for 
efficient pre-mRNA splicing and splice site selection.44,57,58 
We found that GPATCH8 in common with other splic-
ing factors contains ultraconserved poison exons that, in 
other genes, form part of an autoregulatory network cou-
pling alternative splicing to nonsense-mediated decay.46 
RBFOX sites flank both alternatively spliced poison exons 
in GPATCH8 suggesting that RBFOX proteins also regu-
late alternative splicing of GPATCH8.37 Collectively, our 
data suggest that ZNF804A and its paralogs are likely 
to be involved in the regulation of gene expression at the 
level of pre-mRNA splicing but do not preclude a role for 
ZNF804A in translational regulation as recently reported 
by Zhou et al.25
To further investigate the role of ZNF804A in gene 
regulation (expression and splicing), we used exon arrays 
to determine the effect of acute ZNF804A depletion on 
the transcriptome of SH-SY5Y neuroblastoma cells. GO 
enrichment analysis showed that DEX genes clustered 
into several categories related to neurodevelopment, 
cell adhesion, and more specifically synaptic adhesion 
complexes (figure  3A and B). Our results are broadly 
Table 1. Enrichment for Differentially Expressed (DEX) and Differentially Spliced Genes in ZNF804A-Depleted Cells Across Selected 
Functional Gene Sets
Gene set
DEX genes Differentially spliced genes
P value P corr. OR 95% CI P value P corr. OR 95% CI
RBFOX 
targets
.48 ns 0.81 0.46–1.35 4.14 × 10–10 1.66 × 10–9 2.32 1.80–2.96
CELF4
targets
.41 ns 1.09 0.88–1.35 .19 ns 1.11 0.95–1.30
Note: gene sets were collated from the original publication; RBFOX targets defined by an integrative modeling approach and transcripts 
bound by the CELF4 RNA-binding protein 36,37. P values and OR were calculated using Fisher’s exact test and corrected (Bonferroni) for 
multiple testing. CI, confidence interval; ns, not significant.
Table 2. Gene Set Enrichment for Differentially Spliced Genes in ZNF804A-Depleted Cells and De Novo Disease Variants.
Gene set Observed Expected Enrichment P value P corr.
SCZ_syn 23 22 1.05 .444 ns
SCZ_mis 53 49.4 1.07 .321 ns
SCZ_LoF 10 7.4 1.35 .211 ns
ASD_syn 94 85.7 1.1 .197 ns
ASD_mis 254 192.1 1.32 1.16 × 10–5 1.39 × 10–4
ASD_LoF 62 28.8 2.16 5.21 × 10–8 6.25 × 10–7
ID_syn 3 4.1 0.727 .78 ns
ID_mis 16 9.3 1.73 .03 ns
ID_LoF 5 1.4 3.61 .01 ns
control_syn 51 44 1.16 .17 ns
control_mis 109 98.8 1.1 .16 ns
control_LoF 20 14.8 1.35 .11 ns
Note: Statistical enrichment for de novo variants in schizophrenia (SCZ), autism spectrum disorder (ASD), and intellectual disability 
(ID) and differentially spliced genes in ZNF804A-depleted cells. De novo variants were collated from Fromer et al54 and Genovese et al.42 
Tests for enrichment were conducted using denovolyzeR.43 Initial P values were corrected (P corr.) for multiple testing (Bonferroni). Only 
corrected P values < .05 were considered statistically significant. ns, not significant.
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consistent with those of Hill et  al26 who showed that 
knockdown of ZNF804A in NPCs resulted in differen-
tial expression of genes enriched for the GO process “cell 
adhesion.”. Furthermore, knockdown of ZNF804A in 
neurons has recently been shown to attenuate neurite out-
growth and promote loss of dendritic spines potentially 
mediated by reduction in the levels of the cell adhesion 
protein neuroligin-4.24
Alternative splicing generates proteomic diversity and 
has previously been proposed to be an important con-
tributory process to the molecular pathogenesis of sev-
eral neuropsychiatric disorders.59 Following the rationale 
that direct interaction between ZNF804A and a range 
of splicing factors may modulate alternative splicing 
patterns of some genes, we used the exon arrays to look 
for changes in alternative splicing in ZNF804A-depleted 
cells. We found that ZNF804A knockdown is also associ-
ated with robust changes in alternative splicing (figure 3, 
extended data set 1). Collectively, differentially spliced 
genes in ZNF804A-depleted cells are also enriched for 
RBFOX targets, again suggesting that both proteins may 
interact to regulate the splicing of a subset of neuronal 
genes (table 1).
Finally, we used gene set enrichment analysis to search 
for associations between DEX and differentially spliced 
genes in ZNF804A-depleted cells and genes implicated in 
several common neurodevelopmental disorders. We found 
that genes harboring de novo mutations (missense and 
LoF) in ASD show enrichment for differentially spliced 
(and to a lesser extent DEX among LoF variants) genes 
in ZNF804A-depleted cells (table 2). Common and rare 
variants implicated in schizophrenia, ASD, and ID are 
also enriched for RBFOX targets.7,54,60–63 Furthermore, 
RBFOX1 copy number variants have been reported in 
ASD64 whereas RBFOX1 common variants have recently 
been shown to confer increased risk of schizophrenia.7 
The gene set of differentially spliced genes in ZNF804A-
depleted cells was also enriched for common variant 
alleles associated with schizophrenia, bipolar disorder 
and schizophrenia, and ASD. These data suggest that 
ZNF804A may contribute to neurodevelopmental disease 
risk through splicing regulation.
In conclusion, we present convergent evidence that 
ZNF804A is involved in the regulation of gene expres-
sion and alternative splicing in SH-SY5Y cells. Our data 
suggest that ZNF804A regulates the expression of genes 
essential for nervous system development and synap-
tic contact. These data provide novel insights into the 
function of ZNF804A and suggest that ZNF804A may 
interact with splicing factors such as the RBFOX fam-
ily to regulate pre-mRNA splicing in the brain. Genetic 
variation in components of this pathway could mediate 
increased risk of schizophrenia and ASD through con-
certed changes in alternative splicing and gene expression 
of important neurodevelopmental genes.
Supplementary Material
Supplementary data are available at Schizophrenia 
Bulletin online.
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